[go: up one dir, main page]

MA37811B1 - Solution d'acétaminophène injectable sursaturée pour l'administration spinale - Google Patents

Solution d'acétaminophène injectable sursaturée pour l'administration spinale

Info

Publication number
MA37811B1
MA37811B1 MA37811A MA37811A MA37811B1 MA 37811 B1 MA37811 B1 MA 37811B1 MA 37811 A MA37811 A MA 37811A MA 37811 A MA37811 A MA 37811A MA 37811 B1 MA37811 B1 MA 37811B1
Authority
MA
Morocco
Prior art keywords
spinal administration
acetaminophen
injectable
supersaturated
acetaminophen solution
Prior art date
Application number
MA37811A
Other languages
English (en)
Other versions
MA37811A1 (fr
Inventor
Augusto Mitidieri
Elisabetta Donati
Nicola Caronzolo
Original Assignee
Sintetica S A
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=46690603&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA37811(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sintetica S A filed Critical Sintetica S A
Publication of MA37811A1 publication Critical patent/MA37811A1/fr
Publication of MA37811B1 publication Critical patent/MA37811B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
    • A61K31/24—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group having an amino or nitro group
    • A61K31/245—Amino benzoic acid types, e.g. procaine, novocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0085—Brain, e.g. brain implants; Spinal cord
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A61P23/02—Local anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Neurosurgery (AREA)
  • Engineering & Computer Science (AREA)
  • Psychology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Emergency Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Anesthesiology (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La présente invention concerne une solution aqueuse injectable d'acétaminophène à utiliser dans le traitement ou dans la prévention de la douleur par administration spinale, ladite solution injectable d'acétaminophène étant sursaturée. Dans certains modes de réalisation, la solution aqueuse injectable d'acétaminophène est administrée simultanément, séparément ou séquentiellement avec un anesthésique local par administration spinale.
MA37811A 2012-06-29 2013-06-27 Solution d'acétaminophène injectable sursaturée pour l'administration spinale MA37811B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IT001154A ITMI20121154A1 (it) 2012-06-29 2012-06-29 Soluzione iniettabile di acetaminofene per la somministrazione spinale
PCT/IB2013/055277 WO2014002042A1 (fr) 2012-06-29 2013-06-27 Solution d'acétaminophène injectable sursaturée pour l'administration spinale

Publications (2)

Publication Number Publication Date
MA37811A1 MA37811A1 (fr) 2016-10-31
MA37811B1 true MA37811B1 (fr) 2017-07-31

Family

ID=46690603

Family Applications (1)

Application Number Title Priority Date Filing Date
MA37811A MA37811B1 (fr) 2012-06-29 2013-06-27 Solution d'acétaminophène injectable sursaturée pour l'administration spinale

Country Status (44)

Country Link
US (2) US11344517B2 (fr)
EP (1) EP2874602B1 (fr)
JP (1) JP5876620B2 (fr)
KR (1) KR102118227B1 (fr)
CN (1) CN104487051B (fr)
AP (1) AP2014008152A0 (fr)
AR (1) AR091633A1 (fr)
AU (1) AU2013282753B2 (fr)
BR (1) BR112014032818B1 (fr)
CA (1) CA2876801C (fr)
CL (1) CL2014003536A1 (fr)
CO (1) CO7240357A2 (fr)
CR (1) CR20150036A (fr)
CU (1) CU20140150A7 (fr)
CY (1) CY1117691T1 (fr)
DK (1) DK2874602T3 (fr)
DO (1) DOP2014000302A (fr)
EA (1) EA028909B1 (fr)
EC (1) ECSP15000500A (fr)
ES (1) ES2578012T3 (fr)
GE (1) GEP201706689B (fr)
HR (1) HRP20160706T1 (fr)
HU (1) HUE029431T2 (fr)
IL (1) IL236423A (fr)
IT (1) ITMI20121154A1 (fr)
MA (1) MA37811B1 (fr)
MD (1) MD4537C1 (fr)
ME (1) ME02431B (fr)
MX (1) MX369264B (fr)
MY (1) MY169251A (fr)
NI (1) NI201400147A (fr)
NZ (1) NZ703829A (fr)
PE (1) PE20150331A1 (fr)
PH (1) PH12015500178B1 (fr)
PL (1) PL2874602T3 (fr)
PT (1) PT2874602T (fr)
RS (1) RS54844B1 (fr)
SG (2) SG11201408479WA (fr)
SI (1) SI2874602T1 (fr)
SM (1) SMT201600248B (fr)
TN (1) TN2014000526A1 (fr)
UA (1) UA117101C2 (fr)
WO (1) WO2014002042A1 (fr)
ZA (1) ZA201409478B (fr)

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5766321A (en) * 1993-04-14 1998-06-16 Nippon Sanso Corporation Apparatus for reducing dissolved oxygen
US6171298B1 (en) * 1996-05-03 2001-01-09 Situs Corporation Intravesical infuser
FR2751875B1 (fr) 1996-08-05 1998-12-24 Scr Newpharm Nouvelles formulations liquides stables a base de paracetamol et leur mode de preparation
FR2809619B1 (fr) 2000-06-06 2004-09-24 Pharmatop Nouvelles formulations aqueuses de principes actifs sensibles a l'oxydation et leur procede d'obtention
DE10112325A1 (de) * 2001-03-13 2002-10-02 Fresenius Kabi De Gmbh Lagerstabile Fertiginfusionslösungen des Paracetamols
EE200400094A (et) * 2001-12-18 2004-08-16 Uni-Pharma Kleon Tsetis Pharmaceutical Laboratoires S.A. Paratsetamooli parenteraalne kompositsioon
FR2851164B1 (fr) 2003-02-14 2005-04-22 Xuan Tho Nguyen Formulation liquide injectable de paracetamol
DE102005037653A1 (de) * 2005-08-05 2007-02-15 Theraselect Gmbh Stabile, flüssige Formulierung von Paracetamol
WO2008009756A1 (fr) * 2006-07-18 2008-01-24 Genfarma Laboratorio S.L. Formulation liquide injectable de paracétamol
CN101015542A (zh) * 2007-02-13 2007-08-15 天津生机集团有限公司 家畜用复方对乙酰氨基酚注射液及其制备方法
MD3528G2 (ro) * 2007-09-28 2008-11-30 Сергей ШАНДРУ Metodă de anestezie spinală continuă la pacienţii în etate
US9399012B2 (en) * 2007-11-13 2016-07-26 Mallinckrodt Ip Reduced dose intravenous acetaminophen
WO2009098716A2 (fr) 2008-01-17 2009-08-13 Aptuit Laurus Private Limited Compositions pharmaceutiques aqueuses stables
WO2009143558A1 (fr) 2008-05-26 2009-12-03 Silphion Pty Limited Formulations injectables
EP2243477A1 (fr) 2009-04-22 2010-10-27 Fresenius Kabi Deutschland GmbH Paracétamol destiné à l'administration parentérale
JP2013006770A (ja) 2009-10-09 2013-01-10 Ssp Co Ltd アセトアミノフェン含有経口液剤
UA109544C2 (uk) * 2010-06-30 2015-09-10 Фармацевтична композиція, що містить парацетамол, та спосіб її виготовлення

Also Published As

Publication number Publication date
PE20150331A1 (es) 2015-03-07
CA2876801C (fr) 2020-11-03
PH12015500178A1 (en) 2015-04-06
KR102118227B1 (ko) 2020-06-03
CN104487051A (zh) 2015-04-01
US11344517B2 (en) 2022-05-31
DK2874602T3 (en) 2016-07-04
EP2874602B1 (fr) 2016-03-30
JP5876620B2 (ja) 2016-03-02
GEP201706689B (en) 2017-06-26
EA028909B1 (ru) 2018-01-31
HRP20160706T1 (hr) 2016-08-12
EA201500065A1 (ru) 2015-10-30
DOP2014000302A (es) 2015-03-15
SI2874602T1 (sl) 2016-09-30
PH12015500178B1 (en) 2021-08-04
CU20140150A7 (es) 2015-10-27
IL236423A0 (en) 2015-02-26
WO2014002042A1 (fr) 2014-01-03
HUE029431T2 (en) 2017-03-28
MX2014015402A (es) 2015-06-17
AU2013282753B2 (en) 2017-03-02
UA117101C2 (uk) 2018-06-25
ZA201409478B (en) 2016-01-27
SG11201408479WA (en) 2015-01-29
US20160128955A1 (en) 2016-05-12
MD20140138A2 (ro) 2015-06-30
CN104487051B (zh) 2017-12-12
SG10201704482YA (en) 2017-07-28
MA37811A1 (fr) 2016-10-31
PT2874602T (pt) 2016-07-13
CL2014003536A1 (es) 2015-05-08
ES2578012T3 (es) 2016-07-20
ITMI20121154A1 (it) 2013-12-30
CA2876801A1 (fr) 2014-01-03
BR112014032818A2 (pt) 2017-06-27
MD4537B1 (ro) 2017-12-31
MY169251A (en) 2019-03-19
CR20150036A (es) 2015-03-13
AR091633A1 (es) 2015-02-18
EP2874602A1 (fr) 2015-05-27
MD4537C1 (ro) 2018-07-31
BR112014032818B1 (pt) 2022-06-14
US20150148379A1 (en) 2015-05-28
IL236423A (en) 2017-07-31
NZ703829A (en) 2016-06-24
ECSP15000500A (es) 2015-11-30
PL2874602T3 (pl) 2016-10-31
ME02431B (fr) 2016-09-20
JP2015522004A (ja) 2015-08-03
MX369264B (es) 2019-11-04
CO7240357A2 (es) 2015-04-17
AP2014008152A0 (en) 2014-12-31
CY1117691T1 (el) 2017-05-17
TN2014000526A1 (en) 2016-03-30
NI201400147A (es) 2015-04-13
RS54844B1 (sr) 2016-10-31
SMT201600248B (it) 2016-08-31
AU2013282753A1 (en) 2015-02-05
KR20150027160A (ko) 2015-03-11

Similar Documents

Publication Publication Date Title
RU2016105581A (ru) Способ лечения острого, хронического и подострого кашля и непреодолимого желания откашляться
EA201101709A1 (ru) Полициклические антагонисты рецепторов лизофосфатидной кислоты
ME02910B (fr) Composés tétrahydropyrrolothiazines
EA201590748A1 (ru) Противовирусные соединения против rsv
EA201591403A1 (ru) Спиролактамные модуляторы рецептора nmda и их применение
MY197558A (en) Methods of treating depression using orexin-2 receptor antagonists
FR2962649B1 (fr) Traitement d'une pathologie liee a un effet excessif du tnf par un compose de benzene sulfonamide
MA39146A1 (fr) Combinaisons de gabapentanoïdes et de ligands des récepteurs sigma
EA201791662A1 (ru) Цебранопадол для лечения от боли субъектов с нарушенной печеночной и/или нарушенной почечной функцией
BR112012017994B8 (pt) composição líquida, uso de uma composição líquida, e, métodos para preparar uma composição líquida e para tratamento de um distúrbio
BRPI0907220A2 (pt) métodos de tratar distúrbios de perda óssea usando um antagonista de gm-csf
EA201591123A1 (ru) Комбинации агониста glp1r и метформина, а также способ их применения при лечении диабета 2 типа и прочих расстройств
MA39447B1 (fr) Pirlindole ou ses sels pharmaceutiquement acceptables pour une utilisation en médecine
EA201992685A1 (ru) Раствор леводопы для инфузий
FR2961695B1 (fr) Utilisation de composes dans le traitement ou la prevention de troubles cutanes
EA201990668A1 (ru) Фармацевтическая композиция, содержащая антагонист минералокортикоидных рецепторов, и ее применение
EA201591653A1 (ru) Композиции для лечения глазных расстройств с применением дипиридамола
EA201990550A1 (ru) Офтальмологический препарат, включающий азоловое соединение
MA39448A1 (fr) (r)-pirlindole et ses sels pharmaceutiquement acceptables destinés à un usage médical
MA37811A1 (fr) Solution d'acétaminophène injectable sursaturée pour l'administration spinale
EA201792170A1 (ru) Производные индола
EA201590415A1 (ru) Производные диазепинона, применимые для лечения синдрома хрупкой х-хромосомы, болезни паркинсона или рефлюксного заболевания
EA201690762A1 (ru) {4-[5-(3-хлорфенокси)оксазоло[5,4-d]пиримидин-2-ил]-2,6-диметилфенокси}уксусная кислота для применения при предупреждении или лечении острого повреждения почек
EA201691218A1 (ru) Агонисты a1-аденозиновых рецепторов в качестве лекарственного средства для лечения заболеваний почек
RU2013127881A (ru) Применение фармацевтической композиции на основе соли четвертичного фосфония и замещенного динитробензофуроксана для лечения пироплазмоза у собак и способ лечения